S1 Table. Preferred reporting items for systematic reviews and meta-analyses checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4-5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7

Risk of bias in individual	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether	8
studies		this was done at the study or outcome level), and how this information is to be used in any data synthesis.	
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results 14		Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	8

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, addicating which were pre-specified.	
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9
Study characteristics			9
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	9
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	12
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	12
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	13
DISCUSSION			
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).		13	
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	16

Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	17
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	17

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

S2 Table. Search strategy in Medline (Pubmed)

Search	Virus
#1	"HRSV" OR "RSV" OR "human respiratory syncytial virus" OR "respiratory
	syncytial virus" OR "HRSV-A" OR "HRSV-B" OR "HMPV" OR "MPV" OR
	"human metapneumovirus" OR "metapneumovirus" OR "HMPV-A" OR "HMPV-
	B" OR "HAdV" OR "AdV" OR "Adenovirus" OR "Adenovirus Infections,
	Human" OR "Human adenovirus" OR "HADV-A" OR "HADV-B" OR "HADV-
	C" OR "HADV-D" OR "HADV-E" OR "HADV-F" OR "HADV-G" OR "HBoV"
	OR "BoV" OR "Bocavirus" OR "Bocavirus Infections, Human" OR "Human
	Bocavirus" OR "HCoV" OR "CoV" OR "Coronavirus" OR "Coronavirus
	Infections, Human" OR "Human Coronavirus" OR "229E" OR "OC43" OR
	"NL63" OR "HKU1" OR "HCoV-229E" OR "HCoV-OC43" OR "HCoV-NL63"
	OR "HCoV-HKU1" OR "HPIV" OR "PIV" OR "Parainfluenzavirus" OR
	"Parainfluenzavirus Infections, Human" OR "Human Parainfluenzavirus" OR
	"PIV-1" OR "PIV-2" OR "PIV-3" OR "PIV-4" OR "HPIV-1" OR "HPIV-2" OR
	"HPIV-3" OR "HPIV-4" OR "HEV" OR "EV" OR "Enterovirus" OR "Enterovirus
	Infections, Human" OR "Human Enterovirus" OR "HRV" OR "RV" OR
	"Rhinovirus" OR "Rhinoviruses" OR "Rhinovirus Infections, Human" OR "Human
	Rhinovirus" OR "RV-A" OR "RV-B" OR "RV-C" OR "Influenza" OR "Inf" OR
	"Influenza virus" OR "Influenza, Human" OR "Influenza-A virus" OR "Influenza-
	B virus" OR "Influenza-C virus"
#2	bronchiolitis
#3	#1 AND #2

S3 Table. Items for risk of bias assessment

Hoy et al. tool for cross sectional studies	Yes (1)/No (0)
External validity	
1. Was the study's target population a close representation of the	1
national population in relation to relevant variables?	
2. Was the sampling frame a true or close representation of the	1
bronchiolitis population?	
3. Was some form of random selection used to select the sample,	1
OR was a census undertaken?	
4. Was the likelihood of non response bias minimal?	1
Internal validity	
5. Were data collected directly from the subjects (as opposed to a	1
proxy)?	
6. Was an acceptable bronchiolitis case definition used in the	1
study?	
7. Was the study viral detection assay shown to have validity and	1
reliability?	
8. Was the same mode type of sample collected for all subjects?	1
9. Was the length of the shortest prevalence period for the	1
parameter of interest appropriate?	
10. Were the numerator(s) and denominator(s) for the parameter of	1
interest appropriate?	
Total score	10
Interpretation of the risk of bias tool	
• 7-10: Low risk of bias	
• 4-6: Moderate risk of bias	
• 0-3: High risk of bias	

S4 Table. Main reasons of exclusion of eligible studies

N°	Name, Year	Title	Reason of
			exclusion
1	Akhras, 2010	Human metapneumovirus and respiratory	No molecular
		syncytial virus: subtle differences but comparable	assays used
		severity	
2	Alonso, 2007	Bronchiolitis due to respiratory syncytial virus in	Only positive
		hospitalized children: a study of seasonal rhythm.	samples included
3	Al-Shawwa,	Clinical and therapeutic variables influencing	No molecular
	2007	hospitalisation for bronchiolitis in a community-	assays used
		based paediatric group practice	
4	Al-Shehri, 2005	Bronchiolitis in Abha, Southwest Saudi Arabia:	No molecular
	·	viral etiology and predictors for hospital	assays used
		admission.	
5	Alvarez, 2013	Epidemiological and genetic characteristics	Systematic review
	, , , , , , , , , , , , , , , , , , , ,	associated with the severity of acute viral	3
		bronchiolitis by respiratory syncytial virus.	
6	Amér, 2009	[Not only RSV can cause bronchiolitis in small	Full text not found
		children	
7	Bakalovic, 2015	Epidemiological Features of Bronchiolitis in the	Data on detection
•	2411410 (10, 2010	Pediatric Clinic of Clinical center of Sarajevo	assay not reported
		University.	assay not reported
8	Barr, 2018	Change in viral bronchiolitis management in	No data on viral
O	Dui1, 2010	hospitals in the UK after the publication of NICE	etiology searched
		guideline.	chology searched
9	Bashir, 2017	Respiratory syncytial virus and influenza are the	Not possible to
	Bushin, 2017	key viral pathogens in children <2 years	extract data on
		hospitalized with bronchiolitis and pneumonia in	viral etiology
		Islamabad Pakistan.	searched
10	Bauert, 2019	Rhinovirus Species in Children With Severe	Duplicates
10	Baacit, 2019	Bronchiolitis: Multicenter Cohort Studies in the	Bupileaces
		United States and Finland	
11	Bennett, 2018	Population-based trends and underlying risk	Inappropriate
	20111000, 2010	factors for infant respiratory syncytial virus and	study population
		bronchiolitis hospitalizations.	stady population
12	Berezin, 2006	Rhinovirus and bronchiolitis.	Comments
13	Bilavsky, 2010	Respiratory syncytial virus-positive bronchiolitis	No molecular
13	Dilavsky, 2010	in hospitalized infants is associated with	assays used
		thrombocytosis.	assays useu
14	Pachlan 2020	A 14-year Prospective Study of Human	Inappropriate
14	Bochkov, 2020		
		Comparison With Other Peninstony Virges	study population
15	Bouscambert-	Comparison With Other Respiratory Viruses.	Duplicate of
13		Detection of human metapneumovirus RNA	Duplicate of
	Duchamp, 2005	sequences in nasopharyngeal aspirates of young	Janahi, 2017
		French children with acute bronchiolitis by real-	
		time reverse transcriptase PCR and phylogenetic	
1.6	Doving 2004	analysis. Incidence of bronchiolitis-associated	Commonts
16	Boyce, 2004		Comments
		hospitalization among children in Olmsted	
17	D 2016	County, Minnesota.	G .
17	Boyce, 2016	More on Viral Bronchiolitis in Children.	Comments

18	Bradley, 2005	Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke	Only positive samples included
		exposure and atopy.	samples included
19	Brini, 2018	Temporal and climate characteristics of	No molecular
1)	Dinn, 2010	respiratory syncytial virus bronchiolitis in	assays used
		neonates and children in Sousse, Tunisia, during a	assays used
		13-year surveillance	
20	Brini, 2020	Temporal and climate characteristics of	Inappropriate
		respiratory syncytial virus bronchiolitis in	detection assay
		neonates and children in Sousse, Tunisia, during a	
		13-year surveillance.	
21	Calvo, 2015	Respiratory Syncytial Virus Coinfections With	> 2 years
		Rhinovirus and Human Bocavirus in Hospitalized	
		Children	
22	Cantani, 1999	Bronchiolitis in infants.	No data on viral
22	G 2007		etiology searched
23	Causse, 2007	Preliminary evaluation of a multiplex reverse	> 2 years
		transcription-PCR assay combined with a new	
		DNA chip hybridization assay for detecting	
24	Cavallin, 2013	respiratory syncytial virus Infection with multiple viruses is not associated	Comments
4	Cavanin, 2013	with increased disease severity in children with	Comments
		bronchiolitis.	
25	Centers for	Bronchiolitis-associated outpatient visits and	Report
20	Disease Control	hospitalizations among American Indian and	Report
	and Prevention	Alaska Native childrenUnited States, 1990-	
	(CDC), 2003	2000.	
26	Chan, 2002	Risk factors for hypoxemia and respiratory failure	Only positive
		in respiratory syncytial virus bronchiolitis.	samples included
27	Chee, 2010	Emergency Department Septic Screening in	No molecular
		Respiratory Syncytial Virus (RSV) and Non-RSV	assays used
		Bronchiolitis.	
28	Chen, 2004	[Clinical characteristics of bronchiolitis caused	Full text not found
20	G1 2014	by human metapneumovirus in infants]	G 1: .: .:
29	Chen, 2014	Viral etiology of bronchiolitis among pediatric	Combination of
		inpatients in northern Taiwan with emphasis on	multiple asays for
30	Ciarlitto, 2019	newly identified respiratory viruses. Respiratory Syncityal Virus A and B: three	detection
30	Ciarinto, 2019	bronchiolitis seasons in a third level hospital in	Inappropriate study population
		Italy.	study population
31	Connors, 2016	Viral Bronchiolitis in Children.	Comments
32	Coskun, 2017	Risk factors for intensive care need in children	Data on detection
34	COSKUII, 2017	with bronchiolitis: A case-control study.	assay not reported
33	Côté, 2003	Comparative evaluation of real-time PCR assays	No data on viral
	2000, 2000	for detection of the human metapneumovirus	etiology searched
34	CRONE, 1964	SEROLOGICAL EVIDENCE OF INFECTION	No molecular
	Í	BY RESPIRATORY SYNCYTIAL VIRUS IN	assays used
		OUTBREAK OF ACUTE BRONCHIOLITIS	
35	Cubie, 1992	Detection of respiratory syncytial virus in acute	Not possible to
		bronchiolitis in infants	extract data on
			viral etiology
			searched

36	Dagan, 1993	Hospitalization of Jewish and Bedouin infants in	No molecular
		southern Israel for bronchiolitis caused by	assays used
		respiratory syncytial virus	
37	Davies, 2017	A systematic review of the psychometric	Systematic review
		properties of bronchiolitis assessment tools.	
38	DeVincenzo,	Viral Bronchiolitis in Children.	Comments
	2016		
39	Dotan, 2013	Hospitalization for respiratory syncytial virus	Only positive
		bronchiolitis and disease severity in twins.	samples included
40	Duttweiler, 2004	Pulmonary and systemic bacterial co-infections in	Only positive
		severe RSV bronchiolitis.	samples included
41	Eidelman, 2009	The burden of respiratory syncytial virus	No molecular
		bronchiolitis on a pediatric inpatient service.	assays used
42	Erculj, 2018	PM10 exposure is associated with increased	Only positive
		hospitalizations for respiratory syncytial virus	samples included
		bronchiolitis among infants in Lombardy, Italy.	
43	Erez, 2012	[Prevalence of H1N1 A influenza virus infection	Full text not found
		among hospitalized patients with bronchiolitis	
		twelve months old and younger]	
44	Eugene-Ruellan,	Detection of respiratory syncytial virus A and B	Age range not
	1998	and parainfluenzavirus 3 sequences in respiratory	reported
		tracts of infants by a single PCR with primers	
		targeted to the L-polymerase gene and differential	
4.5	EANIDDE 1064	hybridization	F-11 4 4 F 1
45	FANDRE, 1964	[EPIDEMIC OF ACUTE BRONCHIOLITIS IN INFANTS. ISOLATION OF A RESPIRATORY	Full text not found
		SYNEYTIAL VIRUS	
46	Fauroux, 2017	The Burden and Long-term Respiratory Morbidity	Systematic review
40	Tauroux, 2017	Associated with Respiratory Syncytial Virus	Systematic review
		Infection in Early Childhood.	
47	Fedele, 2018	Analysis of the immune response in infants	Inappropriate
т,	1 cdc1c, 2010	hospitalized with viral bronchiolitis shows	study population
		different Th1/Th2 profiles associated with	population
		respiratory syncytial virus and human rhinovirus.	
48	Ferronato, 2012	Etiological diagnosis reduces the use of antibiotics	No molecular
		in infants with bronchiolitis.	assays used
49	Fjaerli, 2004	Hospitalisations for respiratory syncytial virus	No molecular
	3	bronchiolitis in Akershus, Norway, 1993-2000: a	assays used
		population-based retrospective study.	
50	Flaherman, 2010	Respiratory syncytial virus testing during	No molecular
		bronchiolitis episodes of care in an integrated	assays used
		health care delivery system: a retrospective cohort	
		study.	
51	Flamant, 2005	Severe respiratory syncytial virus bronchiolitis in	No molecular
		children: from short mechanical ventilation to	assays used
		extracorporeal membrane oxygenation.	
52	Flores, 2004	Bronchiolitis caused by respiratory syncytial virus	> 2 years
		in an area of portugal: epidemiology, clinical	
		features, and risk factors.	
53	Fodha, 2007	Respiratory syncytial virus infections in	Only positive
		hospitalized infants: association between viral	samples included
		load, virus subgroup, and disease severity	

54	Foley, 2018	Respiratory health inequality starts early: The	No molecular
		impact of social determinants on the aetiology and	assays used
		severity of bronchiolitis in infancy.	
55	Foo, 1991	Severe bronchiolitis in children	Full text not found
56	FORBES, 1961	Epidemic bronchiolitis caused by a respiratory	Conference
	·	syncytial virus: clinical aspects	abstract
57	Fretzayas, 2017	Etiology and clinical features of viral bronchiolitis	Review
	•	in infancy.	
58	Freymouth,	Presence of the new human metapneumovirus in	Age range not
	2003	French children with bronchiolitis.	reported
59	Fujiogi, 2020	Association of rhinovirus species with	Duplicates
		nasopharyngeal metabolome in bronchiolitis	
		infants: A multicenter study.	
60	Ganu, 2012	Increase in use of non-invasive ventilation for	Data on detection
		infants with severe bronchiolitis is associated with	assay not reported
		decline in intubation rates over a decade	
61	Garcia, 2010	Risk factors in children hospitalized with RSV	No molecular
		bronchiolitis versus non-RSV bronchiolitis.	assays used
62	Garcia-Marcos,	Pediatricians' attitudes and costs of bronchiolitis	No data on viral
	2014	in the emergency department: a prospective	etiology searched
	G1 1 2010	multicentre study.	
63	Ghazaly, 2018	Characteristics of children admitted to intensive	Combination of
		care with acute bronchiolitis.	multiple asays for
<i>C</i> 1	Cl 1 2010	Characteristics of dillarge decided to intensive	detection
64	Ghazaly, 2018	Characteristics of children admitted to intensive	Inappropriate
65	Ciondono 2019	care with acute bronchiolitis.	detection assay
03	Giordano, 2018	Respiratory syncytial virus bronchiolitis and hypertransaminasemia.	Case report
66	Gold, 2006	[Respiratory syncytial virus bronchiolitis: severe	Review
00	G010, 2000	respiratory forms in hospitalized infants]	Review
67	González	[Clinical impact of introducing ventilation with	No molecular
07	Martínez, 2013	high flow oxygen in the treatment of bronchiolitis	assays used
	Wartinez, 2013	in a paediatric ward]	assays used
68	Goto-Sugai,	Genotyping and phylogenetic analysis of the	Only positive
00	2010	major genes in respiratory syncytial virus isolated	samples included
		from infants with bronchiolitis.	
69	Greensill, 2003	Human metapneumovirus in severe respiratory	Age range not
**		syncytial virus bronchiolitis.	reported
70	Grimaldi, 2002	[Prospective regional study of an epidemic of	Only positive
	,	respiratory syncytial virus	samples included
71	Grimwood, 2008	Risk factors for respiratory syncytial virus	Combination of
		bronchiolitis hospital admission in New Zealand.	multiple asays for
		-	detection
72	Grubbauer, 1989	[Respiratory insufficiency in acute bronchiolitis	Full text not found
		in infancy]	
73	Haque, 2012	Bronchiolitis outbreak caused by respiratory	Outbreak
		syncytial virus in southwest Bangladesh, 2010.	
74	Hasegawa, 2014	Multicenter study of viral etiology and relapse in	Duplicate of
		hospitalized children with bronchiolitis.	Dumas, 2016
75	Hasegawa, 2014	Infectious pathogens and bronchiolitis outcomes.	Review
76	Hasegawa, 2015	Risk factors for requiring intensive care among	Duplicate of
		children admitted to ward with bronchiolitis.	Dumas, 2016

77	Hasegawa, 2015	Respiratory syncytial virus genomic load and disease severity among children hospitalized with bronchiolitis: multicenter cohort studies in the United States and Finland.	Duplicate of Dumas, 2016
78	Hasegawa, 2018	Rhinovirus Species in Children with Severe Bronchiolitis: Multicenter Cohort Studies in the US and Finland.	Duplicate of Dumas, 2016
79	Hasegawa, 2019	Respiratory Virus Epidemiology Among US Infants With Severe Bronchiolitis: Analysis of 2 Multicenter, Multiyear Cohort Studies.	Duplicates
80	Hasegawa, 2019	Association of Rhinovirus C Bronchiolitis and Immunoglobulin E Sensitization During Infancy With Development of Recurrent Wheeze.	Duplicates
81	Heinonen, 2018	Transient Tachypnea of the Newborn is Associated with an Increased Risk of Hospitalization Due to RSV Bronchiolitis.	Data on detection assay not reported
82	Hendaus, 2014	Does cesarean section pose a risk of respiratory syncytial virus bronchiolitis in infants and children?	> 2 years
83	Henderson, 1979	The etiologic and epidemiologic spectrum of bronchiolitis in pediatric practice	No molecular assays used
84	Hervas, 2012	Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis.	No molecular assays used
85	Houben, 2011	Clinical prediction rule for RSV bronchiolitis in healthy newborns: prognostic birth cohort study	Not bronchiolitis
86	Howidi, 2007	The severity of respiratory syncytial virus bronchiolitis in young infants in the United Arab Emirates.	No molecular assays used
87	Huguenin, 2012	Broad respiratory virus detection in infants hospitalized for bronchiolitis by use of a multiplex RT-PCR DNA microarray system.	Age range not reported
88	Hyvarinen, 2011	Outcome after bronchiolitis depends on disease definition.	Only positive samples included
89	Jacques, 2006	Association of respiratory picornaviruses with acute bronchiolitis in French infants.	Duplicate of Janahi, 2017
90	Jacques, 2008	Human Bocavirus quantitative DNA detection in French children hospitalized for acute bronchiolitis.	> 2 years
91	Jartti, 2015	Rhinovirus-induced bronchiolitis: Lack of association between virus genomic load and short-term outcomes	Duplicate of Dumas, 2016
92	Jelić, 1990	[A bronchiolitis epidemic caused by respiratory syncytial viruses]	Full text not found
93	Jevsnik, 2016	The Role of Human Coronaviruses in Children Hospitalized for Acute Bronchiolitis, Acute Gastroenteritis, and Febrile Seizures: A 2-Year Prospective Study.	> 2 years
94	Jhawar, 2003	Severe bronchiolitis in children.	Review
95	Kabir, 2003	Evaluation of hospitalized infants and young children with bronchiolitis-a multi centre study.	Full text not found
96	Karr, 2009	Infant exposure to fine particulate matter and traffic and risk of hospitalization for RSV	No data on viral etiology searched

		bronchiolitis in a region with lower ambient air pollution.	
97	Kassis, 2009	[The burden and outcomes of acute bronchiolitis among young children hospitalized in Israel]	Full text not found
98	Kemper, 2005	Hospital readmission for bronchiolitis.	No data on viral etiology searched
99	Korppi, 2012	Upper age limit for bronchiolitis: 12 months or 6 months?	Comments
100	Korppi, 2015	Bronchiolitis: the disease of <6-month-old, <12-month-old or <24-month-old infants.	Comments
101	Kua, 2017	Systematic Review and Meta-Analysis of the Efficacy and Safety of Combined Epinephrine and Corticosteroid Therapy for Acute Bronchiolitis in Infants.	Systematic review
102	Laham, 2017	Clinical Profiles of Respiratory Syncytial Virus Subtypes A AND B Among Children Hospitalized with Bronchiolitis.	Duplicate of Dumas, 2016
103	Lanari, 2015	Prenatal tobacco smoke exposure increases hospitalizations for bronchiolitis in infants.	No data on viral etiology searched
104	Lanari, 2015	Risk factors for bronchiolitis hospitalization during the first year of life in a multicenter Italian birth cohort.	No data on viral etiology searched
105	Lanari, 2016	Exposure to vehicular traffic is associated to a higher risk of hospitalization for bronchiolitis during the first year of life.	Full text not found
106	Legg, 2005	Frequency of detection of picornaviruses and seven other respiratory pathogens in infants	Not bronchiolitis
107	Lin, 2009	[Detection of human metapneumovirus and human bocavirus in children with bronchiolitis in east Guangdong area]	Full text not found
108	López-Huertas, 2005	Two RT-PCR based assays to detect human metapneumovirus in nasopharyngeal aspirates	Not bronchiolitis
109	Lowther, 2000	Bronchiolitis-associated hospitalizations among American Indian and Alaska Native children.	No data on viral etiology searched
110	Luo, 2014	A systematic review of predictive modeling for bronchiolitis.	Systematic review
111	Mação, 2011	[Acute bronchiolitis: a prospective study]	Data on detection assay not reported
112	Macfarlane, 2005	RSV testing in bronchiolitis: which nasal sampling method is best?	No molecular assays used
113	Mandal, 2017	Bronchiolitis: Comparative Study between Respiratory Synctial Virus	Comments
114	Mandal, 2017	Bronchiolitis: Comparative Study between Respiratory Synctial Virus (RSV) and Non RSV Aetiology.	Comments
115	Mansbach, 2008	Prospective multicenter study of the viral etiology of bronchiolitis in the emergency department	Not possible to extract data on viral etiology searched
116	Mansbach, 2012	Prospective multicenter study of viral etiology and hospital length of stay in children with severe bronchiolitis	Duplicate of Dumas, 2016
117	Mansbach, 2016	Children Hospitalized with Rhinovirus Bronchiolitis Have Asthma-Like Characteristics.	Duplicate of Dumas, 2016

118	Mansbach, 2016	Respiratory syncytial virus and rhinovirus severe bronchiolitis are associated with distinct	Comments
440	1. 1. 1. 2010	nasopharyngeal microbiota.	D 11 0
119	Mansbach, 2018	Haemophilus-dominant nasopharyngeal microbiota is associated with delayed clearance of respiratory syncytial virus in infants hospitalized for bronchiolitis	Duplicate of Mansbach, 2016
120	Mansbach, 2019	Association between rhinovirus species and nasopharyngeal microbiota in infants with severe bronchiolitis.	Duplicates
121	Mansbach, 2020	Detection of respiratory syncytial virus or rhinovirus weeks after hospitalization for bronchiolitis and the risk of recurrent wheezing.	Duplicates
122	Marguet, 2009	In very young infants severity of acute bronchiolitis depends on carried viruses.	Combination of multiple asays for detection
123	McCuskee, 2014	Bronchiolitis and pneumonia requiring hospitalization in young first nations children in Northern Ontario, Canada.	Not possible to extract data on viral etiology searched
124	McErlean, 2007	Characterisation of a newly identified human rhinovirus, HRV-QPM, discovered in infants with bronchiolitis.	> 2 years
125	McNally, 2014	Vitamin D receptor (VDR) polymorphisms and severe RSV bronchiolitis: a systematic review and meta-analysis.	Systematic review
126	McNamara, 2007	Impact of human metapneumovirus and respiratory syncytial virus co-infection in severe bronchiolitis.	Age range not reported
127	Meissner, 2016	Viral Bronchiolitis in Children.	Comments
128	Meissner, 2016	More on Viral Bronchiolitis in Children.	Comments
129	Meissner, 2016	Viral Bronchiolitis in Children.	Review
130	Mikalsen, 2012	The outcome after severe bronchiolitis is related to gender and virus.	Only positive samples included
131	Miron, 2010	Sole pathogen in acute bronchiolitis: is there a role for other organisms apart from respiratory syncytial virus?	Combination of multiple asays for detection
132	Molinari Such, 2005	Respiratory syncytial virus-related bronchiolitis in Puerto Rico.	Only positive samples included
133	Munoz-Quiles, 2016	Population-based Analysis of Bronchiolitis Epidemiology in Valencia, Spain.	No data on viral etiology searched
134	Murray, 2014	Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study.	No data on viral etiology searched
135	Naja, 2019	Bronchiolitis Admissions in a Lebanese Tertiary Medical Center: A 10 Years' Experience.	Inappropriate study population
136	Najioullah, 2020	Seasonality and coinfection of bronchiolitis: epidemiological specificity and consequences in terms of prophylaxis in tropical climate.	Inappropriate detection assay
137	Narbona-Lopez, 2018	Prevention of syncytial respiratory virus infection with palivizumab: descriptive and comparative analysis after 12 years of use.	Full text not found

138	Nenna, 2017	Modifiable risk factors associated with bronchiolitis.	No data on viral
139	Neves Barreira, 2001	[Relationship between respiratory syncytial virus subtype and clinical severity in bronchiolitis]	Full text not found
140	Nicolai, 2013	Viral bronchiolitis in children: a common condition with few therapeutic options.	Review
141	O'Connor, 2013	The changing epidemiology of the bronchiolitis epidemic in Tallaght Hospital.	Full text not found
142	Oliveira-Santos, 2016	Influence of meteorological conditions on RSV infection in Portugal	No molecular assays used
143	Ong, 2001	A comparison of nested polymerase chain reaction and immunofluorescence for the diagnosis of respiratory infections in children with bronchiolitis, and the implications for a cohorting strategy	No molecular assays used
144	Ozkaya- Parlakay, 2019	Viral Etiology of Bronchiolitis Among Pediatric Patients.	Inappropriate study design
145	Papadopoulos, 2004	Does respiratory syncytial virus subtype influences the severity of acute bronchiolitis in hospitalized infants?	Only positive samples included
146	Paranhos- Baccalà, 2008	Mixed respiratory virus infections	Review
147	Paul, 2017	Respiratory-syncytial-virus- and rhinovirus- related bronchiolitis in children aged <2 years in an English district general hospital.	Not possible to extract data on viral etiology searched
148	Perrin, 1986	[Predictive indicators of the severity of bronchiolitis caused by respiratory syncytial virus in infants]	Full text not found
149	Pichler, 2000	Severe adenovirus bronchiolitis in children.	Case report
150	Pickles, 2015	Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis.	Review
151	Piedimonte, 2014	Respiratory syncytial virus infection and bronchiolitis.	Review
152	Prais, 2003	Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.	No molecular assays used
153	Pruikkonen, 2014	Infants under 6 months with bronchiolitis are most likely to need major medical interventions in the 5 days after onset.	No molecular assays used
154	Rahbarimanesh, 2018	Viral Aetiology of Bronchiolitis in Hospitalised Children in a Tertiary Center in Tehran.	No molecular assays used
155	Rahbarimanesh, 2018	Viral Aetiology of Bronchiolitis in Hospitalised Children in a Tertiary Center in Tehran.	Inappropriate detection assay
156	Ralston, 2009	Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review.	Systematic review
157	Ramagopal, 2016	Demographic, Clinical and Hematological Profile of Children with Bronchiolitis: A Comparative Study between Respiratory Synctial Virus [RSV] and [Non RSV] Groups.	> 2 years
158	Rivera- Sepulveda, 2017	Epidemiology of bronchiolitis: a description of emergency department visits and hospitalizations in Puerto Rico, 2010-2014.	No data on viral etiology searched

valuation of clinical scoring systems No data on viral
n bronchiolitis admitted to the etiology searched
unit.
yncytial Virus Genotypes, Host Only positive
les, and Disease Severity in Young samples included
pitalized With Bronchiolitis.
prolonged length of hospital stay for No molecular
ronchiolitis. assays used
olitis in Children. Comments
Outcome of Diffuse Acute Infectious Combination of
in Adults. multiple asays for
detection
espiratory syncytial virus in acute No molecular
n small children in northern Japan assays used
ated with disease severity in No data on viral
bronchiolitis. etiology searched
piratory syncytial virus bronchiolitis No data on viral
ns in children less than 1 year: 2004- etiology searched
Study between Noninvasive No data on viral
ositive Airway Pressure and Hot etiology searched
igh-flow Nasal Cannulae as a Mode
Support in Infants with Acute
in Pediatric Intensive Care Unit of a
Hospital.
viral load in infants hospitalized Only positive
litis caused by respiratory syncytial samples included
samples metaded
in Infants and Children. Review
n of infants by human Age range not
rirus and human respiratory syncytial reported
gly associated with severe
pacco smoke and admission weight No molecular
bronchiolitis in infants independent assays used
: prospective cohort study.
n The Journal of Pediatrics: Review
on the etiology of acute bronchiolitis
on the ethology of dedic bronemonts
d-li
rean delivery as a predisposing > 2 years
ratory syncytial virus bronchiolitis
associated mortality and estimates No data on viral
syncytial virus-associated deaths etiology searched
ildren, 1979-1997.
parison of three general paediatric No molecular
I similar outcomes for children with assays used
despite different treatment regimens.
ocavirus DNA in nasopharyngeal Case report
occavirus DNA in nasopharyngeal Case report child with bronchiolitis.
child with bronchiolitis. Case report
child with bronchiolitis. al patterns of infant bronchiolitis in a edicaid population. Case report No data on viral etiology searched
child with bronchiolitis. Case report
ith response since it is response to the response since it is represented by the response since it is represented

179	Soo, 2017	Pulmonary hemorrhage as a complication of	Case report
100	G. 1.2000	Respiratory Syncyntial Virus (RSV) bronchiolitis.	NT 1 4 1 1
180	Stempel, 2009	Multiple viral respiratory pathogens in children with bronchiolitis.	No data on viral etiology searched
181	Stevenson, 2016	Prenatal Versus Postnatal Tobacco Smoke	Duplicate of
	,	Exposure and Intensive Care Use in Children	Dumas, 2016
		Hospitalized With Bronchiolitis.	,
182	Stewart, 2019	Association of respiratory viruses with serum	Duplicates
		metabolome in infants with severe bronchiolitis.	1
183	Stollar, 2014	Virologic testing in bronchiolitis: does it change	Combination of
		management decisions and predict outcomes?	multiple asays for
			detection
184	Tecu, 2006	The viral bronchiolites diagnosis in children by	Full text not found
		PCR multiplex	
185	Tecu, 2012	The adenoviral infections in children admitted to	Full text not found
		hospital with pneumonia, acute bronchiolitis or	
		respiratory viral infections.	
186	Toivonen, 2019	Association between rhinovirus species and	Duplicate of
		nasopharyngeal microbiota in infants with severe	Mansbach, 2016
		bronchiolitis	
187	Tortora, 2015	Adenovirus species C detection in children under	> 2 years
		four years of age with acute bronchiolitis or	
100	m 1:	recurrent wheezing.	
188	Toyoshima, 2011	Bronchiolitis caused by pandemic influenza A	Case report
189	Tsolia, 2003	(H1N1) 2009. Epidemiology of respiratory syncytial virus	No molecular
10)	13011a, 2003	bronchiolitis in hospitalized infants in Greece.	assays used
190	Tumba, 2020	Temporal trend of hospitalizations for acute	No data on
170	1 411104, 2020	bronchiolitis in infants under one year of age in	respiratory viruses
		brazil between 2008 and 2015.	prevalence
191	Valdivia, 1997	Analysis of respiratory syncytial virus in clinical	Age range not
	,	samples by reverse transcriptase-polymerase chain	reported
		reaction restriction mapping	•
192	Van	RSV and bronchiolitis.	Comments
	Rostenberghe,		
	2006		
193	van Woensel,	Bronchiolitis hospitalisations in the Netherlands	No data on viral
	2002	from 1991 to 1999.	etiology searched
194	Vicente, 1978	[Etiologic importance of the respiratory syncytial	Full text not found
		virus in bronchiolitis]	
195	Wall, 2016	Viral Bronchiolitis in Children.	Comments
196	Werno, 2004	Human metapneumovirus in children with	> 2 years
		bronchiolitis or pneumonia in New Zealand.	
197	Willson, 2003	Complications in infants hospitalized for	Data on detection
		bronchiolitis or respiratory syncytial virus	assay not reported
100	*** 10"	pneumonia.	
198	Wolfler, 2018	The infant with severe bronchiolitis: from HFNC	Review
100	XX : 1 . 2002	to CPAP and mechanical ventilation.	0.1
199	Wright, 2002	Illness severity, viral shedding, and antibody	Only positive
		responses in infants hospitalized with bronchiolitis	samples included
200	Vitale als C - 1	caused by respiratory syncytial virus.	No doto an educat
200	Yitshak-Sade,	Air Pollution and Hospitalization for Bronchiolitis	No data on viral
	2017	among Young Children.	etiology searched

201	Yi-Wei, 2018	A molecular epidemiological study of respiratory	Inappropriate
		syncytial virus circulating in southern Zhejiang	detection assay
		Province, China, from 2009 to 2014.	
202	Yorita, 2007	Severe bronchiolitis and respiratory syncytial	Data on detection
		virus among young children in Hawaii.	assay not reported
203	Zhang, 2017	[Molecular biological and clinical characteristics	Full text not found
		of respiratory syncytial virus in children with	
		bronchiolitis]	

S5 Table, Individual characteristics of included studies

							S5	Table. Individual character	ristics of inch	nded studies		ń.			
Name, Year	Male (%)	Age 4 05 months + 2 79	Age_Range	Period 0+2011Mw/2012	Design Cross portional	Sampling	Timing	Country	Language	Bias Moderate risk	Setting	Case definition Respectivelying was discrepated by the presence of a population of an upper requirement tract infection followed:	Sample_type	Virus_Searched	Viral_diagnostic_method
							,					Exact Association was diagnosed by the presence of a recent history of an upper respiratory tract infection followed by court of neutraloxy distress with cough, tackpopun, retraction and diffuse crackles, or whereing on annechation, in accordance with the international recommendations on the diagnosis and management of acute breach-holinis (Subscenneittee on diagnosis and management of breach-holinis, 2004).			
Antones, 2010 Ambusides, 2008	Not reported	Not reported Not reported	< 2 Years < 2 Years	Nov/2007-Apr/2008	Cross sectional	Consecutive	Prospective	Portugal	English	Moderate risk Moderate risk	Hospitalized	The same AAP definition was adopted by all hospitals.	Nasonarymeal secretions Nasonarymeal secretions	HRSV: HMPV: Influence: RV: HAdV: HBoV: HPIV: HCoV: EV HRSV: HAdV: HPIV	Real-time PCR PCR
Atay, 2020	59.4	9x2.4 months	< 2 Years	Sep/2011-Apr/2012	Cross sectional	Consecutive sampling	Prospectively	Turkey	English	Moderate risk of bias	Hospitalized Outpatients	The diagnosis of bronchiolitis was based primarily on each patient's history of preceding viral upper respiratory tract infections, restlessness, cough and/or rhinorthus with signs of a respiratory illness including tackprone, intercretal and/or subsocial retractions, accessory muscle use, must librarie, granting, color changes	Nasopharyngeal secretions	HAdV; HCoV; HMPV; HPIV; HRSV; Influenze; RV	Multiplex PCR
Askar, 2014	63.6	6.98 ± 5.53 months	<2 Years	Nov/2011-May/2012	Cross sectional	Consecutive	Prospective	Turkey	English	Low risk	Hospitalized	or asses, whening or cackles, and lower covers naturations (7). Breechiodiss is defined as a constellation of clinical symptoms and signs including a viral upper respiratory prodount followed by increased respiratory effect and whening in children less than 2 years of age4.	Nasopharyngeal secretions	HRSV; HMPV; Influenza; RV; HAdV; HBoV; HPIV; HCoV; EV	Real-time multiplex PCR
Bamberger, 2012	62	17.5 ± 16.6 weeks	< 2 Years	Dec/2005-Mar/2006	Cross sectional	Consecutive	Prospective	brael	English	Low risk	Hospitalized	Acute AB was diagnosed clinically in those subjects with upper respiratory tract infections (URTIs) with cough and by at least two of the following signs: chost retractions, tachypean, wheezing, or rales on asscultation.	Nasopharyngeal secretions	HRSV; HMPV; Influenze; RV; HAdV; HBoV; HPIV	FCR
Bekhof, 2013	54,2	3.2 months	< 2 Years	Dec/2011-Mar/2012	Cross sectional	Consecutive	Prospective	Netherlands	English	Low risk	Hospitalized	Bronchiolitis was defined as acute respiratory disease, accompanied by coryea, cough, inspiratory crackles	Nasopharyngeal secretions	HRSV; HMPV; RV; HAdV; HCsV	PCR
Bekhof, 2019	59	4.9 (1.6-7.0) mo	< 2 Years	Dec-Mar; 2012-2016	Cobort (Baseline data)	Consecutive sampline	Prospectively	Netherlands	English	Moderate risk of bias	Hospitalized	and or expiratory wheezing on auxcultation. Bronchiolisis was defined as acute respiratory disease accompanied by coryza, cough, and impiratory crackles	Nasopharyngeal secretions	EV: HAdV: HCoV: HMPV: HPIV: HRSV: Influenza: RV	Real-time PCR
Brand, 2012	61	4.5 ± 0.39 (months)	< 2 Years	2006-2009 (Nov-Apr)	Cross sectional	Compositive	Proproctice	Pav-Ba	Fredish	Low risk	Houritalized Outrations	and or expiratory wheezing on auxcultation. Bronchiolisis was defined as an acute infection of the lower sirways, characterized by increased respiratory	Nasolurineal secretions	HRSV: HMPV: Influenza: RV: HAdV: HBoV: HPIV: HCoV: EV	BCB
Calvo, 2010	55	5.6 ± 5.7 months	<2 Years	Sept/2005-Aug/2008	Cross sectional	Consecutive	Prospective	Spain	English	Low risk	Hospitalized	effort (tachypens and/or use of accessory expiratory mancles) and emiristory whereins and/or cracibles and/or zeroes. Acute brouchielitis, was diagnosed as the first pisode of acute cesest expiratory dyspeen with previous signs of vital expiratory infection — whether or not this was	Nasopharyngeal secretions	HRSV; HMPV; Influenza; RV; HAdV; HBoV; HPIV; HCoV; EV	PCR
Cangiano, 2016	54.6	Median age 2.13 months	< I Year	2004-2014 (Oct-May)	Cross sectional	Consecutive	Prospective	Italy	English	Low risk	Hospitalized	associated to respiratory distress or measuresia in children under 2 years old.	Nasopharyngeal secretions	HRSV; HMPV; Influenza; RV; HBoV; HPIV; HCoV	FCR
Chen, 2014	67.3	Mean 255.6 days; 95% CI 240.4-270.9 days	<2 Years	Jan 2009-Dec/2010	Cross sectional	Consecutive	Prospective	Chima	English	Low risk	Hospitalized	Acute brouchteditis was clinically defined as the first episode of acute lower respiratory true infection in infutals look that 2 fromths, characterised by the acute onset of cough, tachyproses, retraction, and diffuse crackles on cheat transcharions 9. Acute brouchteditis was defend as the first opisode of cough, thistorbus, wheezing, or rales, with child transfographic findings of over-caraction and persbosochial inflatination with or without authorises is children.	Nasopharyngeal secretions	HMPV; HBoV	PCR
Dong-Keon, 2018 Daras, 2016	Unclear/Not repor	2.8 = 2.4 months K.1 months (SD: 6.7)	< 1 Year	Nov/2016-Feb/2017	Cross sectional	Consecutive sampling	Retrospectively	North Korea	Non english	Moderate risk of bias	Hospitalized	younser than 2 years. Unclear/Not remoted	Nasonharmeal secretions	HRSV	Real-time PCR
	61		<2 Years	2007-2010 (Nov-Mar)	Cross sectional	Consecutive	Prospective	Pinlande	English	Low risk	Hospitalozed	Bronchiolisis (as defined by the American Academy of Pediatrics 28 acute respiratory illness with some combination of rhimits, cough, tachyproses, wheezing, crackles and retractions), and were younger from 2 years. Bronchiolisis (as defined by the American Academy of Pediatrics 28 acute respiratory illness with some	Nasopharyngeal secretions	HRSV; RV	PCR
Danas, 2016	59	5.8 months (SD: 5.2)	<2 Years	2007-2010 (Nov-Mar)	Cross sectional	Consecutive	Prospective	USA	English	Low risk	Hospitalized	combination of rhinitis, cough, tachypnous, wheering, crackles and retractions), and were younger than 2 years.	Nasopharyngeal secretions	HRSV; RV	PCR
Ebihara, 2005 Gokce, 2017	63.6	Not reported 7 ± 6.5 months	<2 Years <2 Years	Oct 2013-Oct 2016	Cross sectional	Consecutive	Prospective Prospective	Turkey	English	Moderate risk Low risk	Hospitalized	Not resorted. The diagnosis of AB was based on at least 2 of the following signs: chest retractions, tachypean, and whorzing or rales on association following viral upper respiratory tract infection in children less fun 24 months of age.	Nasal secretions	HCoV HRSV; HMPV; Influenza; RV; HAdV; HBoV; HPIV; HCoV	PCR RT-PCR
Hendaus, 2018	60.8	3.61 ± 3.56 months	< 2 Years	Jan/2010-Dec/2012	Cross sectional	Consecutive	Retrospective	Qutar	English	Moderate risk	Hospitalized	for the first time. 11 The discretic of brow-birditis was based on the definition supported by the American Academy of polistrics.	Nasopharyngeal secretions	HRSV; RV; HAdV; HBoV; HPIV; HCoV	Real-time PCR
Jamhi, 2017	67	Not reported	<2 Years	2010-2011	Cross sectional	Consecutive	Retrospective	Qutur	English	Low risk	Hospitalized	surcommune on diamosts and management of broachiolisis.1 Acute broachiolisis defined according to International Classification of Disease (KD) code 466.1 in the 9th	Nasopharyngeal secretions	HRSV; HMPV; Influenza; RV; HAdV; HBoV; HPIV; HCoV; EV	Real-time PCR
												subcreasines on diamonic and management of broncholdris. Another broncholdrish of according to the female and Casolifactoris of Discuss (ECD) code 666.1 is the 9th servicies of the ECD Based on recorded clinical diagnosis, an episode of acut broncholdris wa determined by a constillation of clinical signs and systems classified priore, theirst, hoppierse, code; between, tracklor, carefulness, and the state of the clinical priore, theirst, hoppierse, code; between, tracklor, carefulness, and the clinical priore desired priore, their clinical priore desired priore and the clinical priore desired priore desired priore and the priore desired priore and the priore desired priore and the priore desired priore desired priore and the priore desired priore d			
Jami, 2014 Mansbach, 2008	61	K.I months (SD: 6.7)	<2 Years	2007-2010 (Nov-Mar)	Cross sectional	Consecutive	Prospective	Finlande	English	Low risk	Hospitalized	Brenchiolitis (as defined by the American Academy of Pediatrice 28 acute respiratory illness with some combination of thintis, cough, tachypeoca, wheering, cracides and retractions), and were younger fan 2 years.	Nasopharyngeal secretions	HMPV; Influents; RV; HAdV; HPIV; HCoV; EV	PCR
	61	Median age of 6.3 months (IQR 3.1 to 10.2)	<2 Years	Dec/2005-Mar/2006	Coluet	Consecutive	Prospective	USA	English	Moderate risk	Outputients	The diagnosis of broachiolitis was considered for children younger than 2 years with acute tachypeas, retractions, and absortail breach sounds who did not meet criteria for a diagnosis of passuration is exactled printing diagnosis. A defined by the Act of his in 2000 position statement, children with broachiolitis inpically have "rhinitis, tachypnea, wheezing, cough emckles, use of accessory muscles, and ? or nasal flating," 12	Nasopharyngeal secretions	HRSV; RV	RT-PCR
Mansbuch, 2016	Not reported	Not reported	<1 Year	2011-2014 (Nov-Apr)	Cohort	Consecutive	Prospective	USA	English	Low risk	Hospitalized	Bronchiolisis defined by the Academy of Pediatrics: acute respiratory illness with some combination of thinitis,	Nasopharyngeal secretions	HRSV; RV	PCR
Midulla, 2000	57	2.5 ± 2.1 months	< 1 Year	2004-2007 (Oct-May)	Cross sectional	Consecutive	Prospective	haly	English	Low risk	Hospitalized	count, tachomaes, wheering, exceldes, and netractions:1 Breachiolists was diagnosed according to the presence of a bistory of upper respiratory tract infection followed by acute onest of respiratory distress with cough, tachypnea, sortextion and diffuse crackles on association	Nasal secretions	HRSV; HMPV; Influenza; RV; HBoV; HPIV; HCoV	PCR
Midalla, 2018	Not reported	Not reported	<1 Year	2005-2017 (Sep-May)	Cross sectional	Consecutive	Prospective	Buly	English	Low risk	Hospitalized	by actic cent of experiency distress with cough, tachypnea, solvaction and diffuse crackies on assorbation thereine whosersa alone was not considered sufficient for inclusion in the study's 18. Broncholitis was defined as the first episode of acute lower respiratory tract infection in infants loss than 1 year old, chranterined by the acute owns of cough techypneae, retraction, and diffuse crackles (whoseing alone	Nasopharyngeal secretions	HRSV	PCR
Miller, 2013	Not reported	Not reported	<1 Year	2004-2008 (Sept-May)	Cohort	Consecutive	Prospective	USA	Enrish	Low risk	Hospitalized Outputients	was insufficient for inclusion) [28].	Nasopharyngeal secretions	HRSV: HMPV: Influenza: RV: HPTV: HCoV	0.00
	Not reponed			2004-2008 (Sept-May)	Cross sectional					Low risk				HESS, HARPS, Influence, RS, HARS, HRAS, HPPS, HCAS, FV	PC.R
Nascimento, 2010	65	Median age was 6 ± 4 months			Cross sectional	Consecutive	Prospective	Brazil	English	Low risk	Outpatients		Nasopharyngeal secretions		PCR, RT-PCR, Real-time RT-PCR
Nemna, 2020 Nemna, 2020	Unclear/Not report	Unclear Not reported Unclear Not reported	<1 Year	Unclear/Not reported Unclear/Not reported	Cross sectional Cross sectional	Consecutive sampling Consecutive sampling	Prospectively	haly	English	Moderate risk of bias Moderate risk of bias	Hospitalized	infection. Bronchiolisis was defined as the first episode of acute lower airway infection, characterized by a history of upper reopiratory text infection followed by acute omet of respiratory distress with cough, achypenea, retraction and diffuse crackles on assemblation.	Nasopharyngeal secretions Nasopharyngeal secretions	HBoV; HMPV; HRSV; RV HBoV; HMPV; HRSV; RV	Classical PCR Classical RT-PCR
Papadopoulos, 2002	61.3	3.9 шенты	< 1.5 years	Oct/1999-Sep/2000	Cross sectional	Consecutive	Prospective	Greece	English	Low risk	Hospitalized	upper requiratory tea's infection followed by acute ones of receptancy distress with cough, techyprocus, mentaries, and different conductor amendment of the first reported of each bower airway infection, characterized by a history of upper receptancy teat infection followed by acute ones of creopinarsy distress with cough, techyprocus, permettion, and differe creakless or amendment.		HRSV; Influenza; RV; HAdV; HPIV; HCoV	PCR
Papoff, 2011	50.5	Median (interquarile, LQ.) were 61 days (LQ. 33–99 days)	<1 Year	2004-2009 (Oct-May)	Cross sectional	Consecutive	Prospective	Buly	English	Low risk	Hospitalized	(tachypnea [more than 50 respirations/minute] and/or use of accessory respiratory muscles) and expiratory whereing and/or crackles. Broachiolistic was diagnosed clinically according to the presence of a history of upper respiratory tract infection.	Nasal secretions	HRSV; HMPV; Influenza; RV; HBoV; HPIV; HCoV	PCR
												followed by acute onset of requiratory distress with cough, tachypnea, retractions and bilateral crackles on auscultation having wherzing alone was not considered sufficient for inclusion in the study (11).			
Petrarca, 2018 Piedra, 2017	54.1	Median age 2.03 months, range: 0.23-11.17	<1 Year <2 Years	2004-2016 (Oct-May) Oct/2010-Apr/2011	Cross sectional	Consecutive	Retrospective	haly	English	Low risk	Hospitalized	Bronchiolitiewas clinically defined as the first episode of acute lower respiratory tract infection, characterized by the acute onset of cough tachypnea, retraction, and diffuse crackles on chest association in infants younger than 12 months 13	Nasopharyngeal secretions	HRSV; RV	PCR Real-time PCR
Pietex, 2017 Pitrex, 2005	es.	6.7±6.3 months Median 2 (1.2-3.6) months	<2 Years <0.5 year	Oct 2010-Apr 2011 May 2012-Sep 2012	Colora SOCIOREI	Committee	hospective	Read .	Non-continh	Medical sid	Monateliand	than 12 months: 3 Berochiolists was defined as a physician diagnosis in children less than 24 months of age with wheering and/or rates who had abstrore of erecedise senses airway illness. BA was defined as the first opiosde of wheezing, associated with signs and symptoms of acute viral infection.	Nasopharyngeal secretions Nasopharyngeal secretions	au au	RT-PCR
Prirez, 2005 Pramik, 2018	~		<0.5 year <2 Years	May 2012-Sep 2012 May 2014-Oct 2008	Connect	COMMONITOR	rospective	and and	Non english	meneral DIX	respectation	feoryza and counts).		RV HRSV; RV; HBoV	RT-PCR RT-PCR
	61,5	Not reported			Cross sectional	Consecutive	Retrospective	Slovenia	English	Moderate risk	Hospitalized Outputients	Corvoz and counts. Faters were identified through a query of the electronic medical record based on a brouchiolitis diagnosis (RD-10 code 2.11.0-9).	Nasopharyngeal secretions		RT-PCR
Ricart, 2013	Not reported	Not reported	<1 Year	Sep/2007-Oct/2008	Cross sectional	Consecutive	Prospective	Spain	English	Low risk	Hospitalized	Patients were admitted it one of the following criteria was present: pulse country v92% on room air, moderate brencholini, excerding to brencholinis clinical score/3, poor feeding with risk of delphration, apnea, significant congenital heart disease or palmonary brenchodyoplasia, or infant aged <4 weeks.	Nasopharyngeal secretions	HRSV; HMPV; Influenza; RV; HAdV; HBoV; HPIV; HCoV; EV	PCR
Ricart, 2013	Not reported	Not reported	<1 Year	Oct/2007-Oct/2008	Cross sectional	Consecutive	Prospective	Spain	English	Low risk	Hospitalizzed	Brenchiolitis was diagnowed according to the presence of the first acute respiratory tract infection characterized by respiratory distress (uchyprea, use of accessory muscles), cough, widespread crackles, whenring or both, associated with sign of virsi infection (coryaz).	Nasopharyngeal secretions	HRSV; HMPV; Influenza; RV; HAdV; HBoV; HPIV; HCoV; EV	RT-PCR, Real-time RT-PCR
Ricart, 2014	60.8	41.7 (13-70.3) (Mean (95% confidence interval) days)	< 1 Year	Jan/2006-Oct/2008	Cross sectional	Consecutive	Prospective	Spain	English	Low risk	Hospitalized	by requisitory distress (tachypara, use of accessory muscles), cough, widespread crackles, when ring or both, associated with signs of viral infection (creyra). 2 Brenchicilis was diagnosed according to the presence of the first acute respiratory tract infection characterized by respiratory distress, cough, widespread crackles or when ring to both, associated with signs of viral infection (conyra).	Nasopharyngeal secretions	HRSV; HMPV; RV; HAdV; HCoV	PCR
Richard, 2008 Robledo-Aceves, 2018	Not reported 60.5	Not reported 6.60 ± 5.7 months	<1 Year <2 Years	2003-2008 (Sep-Apr) Sep/2002-Jan/2015	Cross sectional Case-control	Consecutive Consecutive	Retrospective Retrospective	France Mexico	English English	Moderate risk Low risk	Hospitalized Hospitalized	Not reported. Severe broochiolitis was defined as thinorthus, ecoph, tachypeus, wheezing, rales, and increased respiratory effort (e.g., graving, most fluring, and interconal and/or subconal retraction), with symptoms of severity (e.g., increased respiratory rate, notractions, and oxygon suturation at 90% or lower). [25]		HRSV: Influence: RV; HAdV: HFTV: EV HRSV; HMFV; Influence; RV; HBoV; HFIV; HCoV	PCR on NASBA RT-PCR, PCR
Salvador García, 2012	53.6	3.4 (± 3.3) months	< 1.5 years	Dec/2008-Apr-2009	Cross sectional	Consecutive	Prospective	Spain	Non english	Low risk	Hospitalized	The diagnosis of broachiolitis was established according to the McConnochie criteria?, defined as the first acute episods of empiratory distress with wheezing associated with catarrhal pathology in children under 2 years of are.	Nasopharyngeal secretions	HRSV; HMPV; Influenza; RV; HAdV; HBoV; HPIV; HCoV; EV	RT-PCR
Soura, 2016	Not reported	Not reported	<1 Year	Sep/2006-Aug/2011	Cross sectional	Consecutive	Prospective	Brazil	English	Lowrisk	Hospitalized	nan to necessity of chief the state of the produceral symptoms, with wheezing, crackkes, and tachypeus); having been recrusted within the first 48 h of hospitalization; and having a ? 72-b history of clinical manifestations of lower respiratory tract infection (wheeze or respiratory distress).	Nasopharyngeal secretions	HRSV; HMPV; RV	Real-time PCR
Suin, 2019 Su-Jin, 2018	53.5 62.6	4 months Unclear/Not reported	<2 Years <2 Years	2016-2018 Nov/2007-May/2015	Cross sectional Cross sectional	Consecutive sampling Consecutive sampling	Prospectively Prospectively	South Korea	rziglish Non english	Moderate risk of bias Low risk of bias	Hospitalized	Unclear/Not remorted Broachiolisis was defined as a clinical syndrome accompanied by symptoms of upper respiratory tract infection	Nasopharyngeal secretions	HRSV EV; HAdV; HBoV; HCoV; HMPV; HPIV; HRSV; Influence; RV	Classical RT-PCR Real-time PCR
Teeratakalpisarn, 2007	Not reported	Not reported	<2 Years	Apr/2002-Aug/2004	Cross sectional	Consecutive	Prospective	Theiland	English	Low risk	Hospitalized	and lower reminators trust infection such as wheering. Breachiolisis was defined as the first epi-sode of wheezing associated with tachypura, in-creased respiratory effort and an useer reminators tract infection.	Nasopharyngeal secretions	HRSV; HMPV	RT-PCR
Tsou, 2020 Unar, 2014	57.4	Unclear/Not reported	<1 Year	Jan/2015-Dec/2017	Case control	Simple random sampling	Prospectively	United States of America	English	Low risk of bias	Hospitalized			HAZV: HCsV: HMPV: HPIV: HRSV	Real-time PCR
	72.5	7.18 ± 5.75 months	<2 Years	Jun 2010-Jun 2000	Cross sectional	Consecutive	Prospective	Turkey	Non english	Low risk	Outpatients	The hand variety was consist nature on the Art Code for concentrative details on since volunte. Disposition of code broadcalistic upper respiratory text infect mand distinctly cough, mild firstly asing, whereing, increased respiratory rate, chest wearing was performed according to the criteria of contrastive time and whereing. Disposits of broadcalistic was defined as the first wheering crisis, beginning no more than 3 days before	Nasopharyngeal secretions	HRSV; HMPV; Influenza; RV; HAdV; HBoV; HPIV; EV	Multiplex PCR
Vieira, 2017 Wang, 2015	68,4	2.4 months (SD = 1.6) Not reported	< 0.5 year < 2 Years	2013-2015 Jan/2010-Dec/2013	Cross sectional Cross sectional	Consecutive	Prospective Prospective	Brazil China	English English	Moderate risk Low risk	Hospitalized Hospitalized	Insertial admission. The bronchiolitis was diagnosed based on the guidelines described by Zhu Futang Practical Pediatrics, 7th	Nasal secretions Nasal secretions	HRSV	Real-time PCR RT-PCR, Real-time RT-PCR
Wollmeister, 2018	Unclear/Not report	Unclear/Not reported	< 1 Year	2004; 2014	Cross sectional	Consecutive sampling	Prospectively	Brazil	English	Moderate risk of bias	Hospitalized	Edition (12). Diagnosis was based on clinical data, which defines AVB as being the first episode of acute respiratory distress with wheeting, preceded by upper airway symptoms such as thinsenhus and cough, with or without fewer [1,5]. The criterion fir severe bronchiolitis was oxygen saturation lower from 92%, which domanded oxygen therapy	Nasopharyngeal secretions	HAdV; HBoV; HCoV; HMPV; HPIV; HRSV; Influence; RV	Classical PCR
Xepapadaki, 2004	Not reported	Not reported	< 1.5 years	Oct/1999-Sep/2000	Cross sectional	Consecutive	Prospective	Greece	English	Low risk	Hospitalized	113. Bronchiolitis, which was defined as an acute infection of the lower airway, characterized by increased respiratory effort (tachypeas of >50 respiration/min and/or use of accessory respiratory mucles), and	Nasopharyngeal secretions	HMPV	PCR
Xuun. 2018 Zhou, 2015		Unclear Not reported	Unclear Not reported	lun/2015-Dec/2016	Cross sectional	Consecutive sampling	Prospectively	China	Non english	Moderate risk of bias	Unclear Not reported		Throat secretions	HBoV: HRSV	Classical PCR
Zhou, 2015	Not reported	Not reported	<2 Years	2012-2014 (winter)	Cross sectional	Consecutive	Prospective	China	English	Low risk	Hospitalized	The diagnosis of broachiolitis is according to the Ziu Fatang textbook of Pudiatrics [Ziang, 2002]. Broachiolitis war diagnosed from the presence of a history of upper separatory text indication followed by audit onest of exopiratory distress with cough, tachgrean, retraction, wheoring, and diffuse crackles on association.	Nasopharyngcal secretions	HKSV	PCR
								•				•			

 $S6\ Table.\ Global\ prevalence\ and\ sensitivity\ analyses\ of\ respiratory\ viral\ infections\ in\ children<2\ years\ with\ bronchiolitis$

	Prevalence [95% CI]	95% Prediction interval	N Studies	N Cases	H [95% CI]	I2 [95% CI]	P-Value Heterogeneity	P-Value Egger test
HRSV								
Overall	59.2 [54.7-63.6]	[29.1-85.9]	45	15351	5.5 [5.1-6]	96.8 [96.2-97.2]	< 0.001	0.415
< 1 Year	62.3 [55.7-68.6]	[32.4-87.8]	18	6779	5.4 [4.7-6.1]	96.5 [95.5-97.3]	< 0.001	0.878
Hospitalized	60.6 [55.9-65.2]	[32.8-85.2]	34	12867	5.3 [4.8-5.8]	96.4 [95.7-97]	< 0.001	0.601
Bronchiolitis definition given	60.4 [56-64.8]	[32.4-85.2]	40	14456	5.3 [4.8-5.7]	96.4 [95.7-97]	< 0.001	0.473
Cross sectional design	57.2 [52.3-62]	[27.2-84.5]	39	12992	5.4 [5-5.9]	96.6 [96-97.2]	< 0.001	0.395
Low risk of bias	59.4 [54.1-64.5]	[30.4-85.2]	30	11024	5.4 [4.9-5.9]	96.5 [95.8-97.2]	< 0.001	0.325
RV								
Overall	19.3 [16.7-22]	[6.3-37]	36	12967	3.7 [3.3-4.2]	92.8 [90.9-94.2]	< 0.001	0.318
< 1 Year	16.9 [13.4-20.7]	[4.8-34]	15	5382	3.4 [2.8-4.1]	91.5 [87.6-94.1]	< 0.001	0.856
Hospitalized	18 [15.1-21.1]	[5-36.4]	28	11159	4 [3.5-4.5]	93.8 [92-95.1]	< 0.001	0.142
Bronchiolitis definition given	19.2 [16.6-22]	[6.2-37.2]	35	12787	3.8 [3.4-4.2]	93 [91.2-94.4]	< 0.001	0.315
Cross sectional design	19.9 [16.9-23.2]	[5.9-39.4]	30	10833	4 [3.5-4.5]	93.6 [91.9-95]	< 0.001	0.315
Low risk of bias	21 [18-24.2]	[8-37.9]	25	9414	3.5 [3-4]	91.6 [88.9-93.7]	< 0.001	0.304
HBoV								
Overall	8.2 [5.6-11.2]	[0-27.3]	24	8706	4.7 [4.1-5.3]	95.4 [94.1-96.4]	< 0.001	0.748
< 1 Year	8 [2.4-16.6]	[0-49]	8	3104	7.3 [6.2-8.6]	98.1 [97.4-98.7]	< 0.001	0.864

	Prevalence [95% CI]	95% Prediction interval	N Studies	N Cases	H [95% CI]	I2 [95% CI]	P-Value Heterogeneity	P-Value Egger test
Hospitalized	8 [5-11.6]	[0-28.6]	18	7335	5.2 [4.5-5.9]	96.2 [95.1-97.1]	< 0.001	0.853
Bronchiolitis definition given	8.2 [5.5-11.3]	[0-27.8]	23	8310	4.8 [4.2-5.4]	95.6 [94.4-96.6]	< 0.001	0.753
Cross sectional design	8.3 [5.6-11.4]	[0-27.6]	23	8572	4.8 [4.2-5.4]	95.6 [94.4-96.6]	< 0.001	0.777
Low risk of bias	9.5 [6.5-13.1]	[0.3-28.2]	17	5578	4.1 [3.5-4.8]	94 [91.8-95.6]	< 0.001	0.331
HAdV								
Overall	6.1 [4.4-8]	[0.2-18.1]	26	6734	3 [2.6-3.5]	88.9 [85-91.8]	< 0.001	0.085
< 1 Year	6.7 [3.6-10.6]	[0-23.1]	7	1938	3 [2.2-4]	88.6 [78.9-93.8]	< 0.001	0.538
Hospitalized	6.1 [4.2-8.4]	[0.1-18.9]	20	5963	3.3 [2.8-3.9]	90.6 [87-93.3]	< 0.001	0.121
Bronchiolitis definition given	6.2 [4.4-8.2]	[0.2-18.2]	24	6386	3 [2.6-3.5]	89 [84.9-92]	< 0.001	0.097
Cross sectional design	6.4 [4.5-8.6]	[0.2-19.2]	23	6112	3.1 [2.6-3.6]	89.5 [85.6-92.4]	< 0.001	0.149
Low risk of bias	6.4 [4.2-8.9]	[0.1-20]	18	4632	3.1 [2.6-3.7]	89.7 [85.2-92.8]	< 0.001	0.052
HPIV								
Overall	5.4 [3.8-7.3]	[0-17.9]	28	7933	3.3 [2.9-3.8]	91 [88.1-93.2]	< 0.001	0.932
< 1 Year	3.1 [1.9-4.6]	[0.1-9.3]	10	3185	2.1 [1.6-2.9]	78.1 [60.1-88]	< 0.001	0.531
Hospitalized	5 [3.3-6.9]	[0-16.7]	21	6707	3.4 [2.9-3.9]	91.1 [87.8-93.5]	< 0.001	0.238
Bronchiolitis definition given	5 [3.4-6.8]	[0-16.7]	26	7585	3.3 [2.8-3.8]	90.6 [87.4-92.9]	< 0.001	0.682
Cross sectional design	5.3 [3.6-7.2]	[0-17.2]	24	6856	3.2 [2.8-3.7]	90.3 [86.8-92.8]	< 0.001	0.528

	Prevalence [95% CI]	95% Prediction interval	N Studies	N Cases	H [95% CI]	I2 [95% CI]	P-Value Heterogeneity	P-Value Egger test
Low risk of bias	5 [3.1-7.2]	[0-18]	20	5831	3.4 [2.9-4]	91.5 [88.3-93.9]	< 0.001	0.983
HMPV								
Overall	5.4 [4.4-6.4]	[1.4-11.5]	32	9908	2.1 [1.8-2.5]	76.9 [67.7-83.5]	< 0.001	0.043
< 1 Year	3.4 [2.4-4.7]	[0.5-8.4]	12	3936	1.9 [1.4-2.5]	71.4 [48.6-84.1]	< 0.001	0.633
Hospitalized	5.1 [4.2-6.1]	[1.9-9.7]	26	8850	1.8 [1.5-2.2]	68.8 [53.2-79.1]	< 0.001	0.238
Bronchiolitis definition given	5.4 [4.4-6.4]	[1.4-11.5]	32	9908	2.1 [1.8-2.5]	76.9 [67.7-83.5]	< 0.001	0.043
Cross sectional design	5.6 [4.6-6.7]	[1.9-11.1]	28	8831	1.9 [1.6-2.3]	72.7 [60.3-81.2]	< 0.001	0.04
Low risk of bias	5.7 [4.5-7]	[1.3-12.8]	26	8034	2.2 [1.9-2.7]	79.6 [70.8-85.8]	< 0.001	0.07
Influenza								
Overall	3.2 [2.2-4.3]	[0-10]	24	6571	2.4 [2-2.8]	82.1 [74.3-87.5]	< 0.001	0.032
< 1 Year	1.6 [0.8-2.6]	[0-5.2]	8	2694	1.7 [1.2-2.5]	65.4 [26.3-83.7]	0.005	0.422
Hospitalized	2.6 [1.8-3.6]	[0.1-7.8]	19	5734	2.1 [1.7-2.6]	77.4 [65.1-85.4]	< 0.001	0.407
Bronchiolitis definition given	3.2 [2.1-4.4]	[0-10.2]	23	6391	2.4 [2-2.9]	82.8 [75.3-88.1]	< 0.001	0.037
Cross sectional design	3 [2-4.3]	[0-10.1]	21	5764	2.4 [2-2.9]	82.8 [74.8-88.3]	< 0.001	0.083
Low risk of bias	3.2 [2.1-4.6]	[0-10.6]	19	5561	2.5 [2.1-3.1]	84.2 [76.7-89.4]	< 0.001	0.08
HCoV								
Overall	2.9 [2-4]	[0-9.9]	27	7431	2.5 [2.1-2.9]	83.5 [76.9-88.1]	< 0.001	0.918
< 1 Year	2.6 [1-4.8]	[0-13.3]	10	3056	3.1 [2.4-4]	89.7 [83.2-93.7]	< 0.001	0.744

	Prevalence [95% CI]	95% Prediction interval	N Studies	N Cases	H [95% CI]	I2 [95% CI]	P-Value Heterogeneity	P-Value Egger test
Hospitalized	2.6 [1.6-3.8]	[0-9.4]	22	6435	2.5 [2.1-3]	84 [76.9-88.9]	< 0.001	0.556
Bronchiolitis definition given	2.9 [2-4.1]	[0-10]	26	7313	2.5 [2.1-3]	84.1 [77.7-88.6]	< 0.001	0.931
Cross sectional design	2.6 [1.7-3.7]	[0-8.8]	23	6354	2.3 [1.9-2.8]	81.1 [72.5-87]	< 0.001	0.744
Low risk of bias	2.8 [1.8-4]	[0-9.4]	20	5559	2.3 [1.9-2.8]	81.5 [72.3-87.6]	< 0.001	0.701
EV								
Overall	2.9 [1.6-4.5]	[0-11.4]	15	4202	2.7 [2.2-3.3]	86.1 [78.6-90.9]	< 0.001	0.886
< 1 Year	2.2 [1.4-3]	[0.7-4.3]	4	1303	1 [1-2.3]	0 [0-80.5]	0.502	0.292
Hospitalized	2.2 [1-3.6]	[0-9.1]	11	3700	2.6 [2-3.3]	84.7 [74.3-90.9]	< 0.001	0.115
Bronchiolitis definition given	2.8 [1.4-4.6]	[0-11.7]	14	4022	2.8 [2.2-3.5]	87 [79.9-91.6]	< 0.001	0.849
Cross sectional design	2.9 [1.5-4.7]	[0-12]	14	3984	2.8 [2.2-3.5]	87 [79.9-91.6]	< 0.001	0.911
Low risk of bias	3.4 [1.7-5.6]	[0-13.5]	11	3386	2.8 [2.2-3.6]	87.7 [79.9-92.5]	< 0.001	0.863

CI: confidence interval; RV: Rhinovirus; HCoV: Human Coronavirus; HPIV: Human Parainfluenzavirus; HMPV: Human Metapneumovirus; HRSV: Human Respiratory Syncytial Virus; HAdV: Human Adenovirus; HBoV: Human Bocavirus; EV: Enterovirus; NA: not applicable.

S7 Table. Subgroup prevalence of respiratory viral infections in children with acute bronchiolitis

	Prevalence [95% CI]	95% Prediction interval	H [95% CI]	N Studies	N Cases	12 [95% CI]	P-Value Heterogeneit y	P-Value Egger test	P-value subgroup difference
HRSV									
Study period									0.304
Continuous study period	57.3 [51.6-62.9]	[26.1-85.6]	4.9 [4.4-5.4]	30	7454	95.8 [94.9-96.6]	< 0.001	0.647	
Interrupted time series study	62.4 [54.3-70.2]	[28.7-90.5]	6.6 [5.8-7.5]	14	7073	97.7 [97-98.2]	< 0.001	0.622	
WHO Region									< 0.001
America	64 [58.2-69.6]	[42.8-82.7]	3.5 [2.8-4.4]	10	4731	92 [87.4-94.9]	< 0.001	0.104	
Eastern Mediterranean	46.9 [40.2-53.7]	[0-100]	2.2 [1.3-4]	3	1240	80 [36.8-93.7]	0.007	0.386	
Europe	59 [52.9-64.9]	[27.4-86.9]	5.3 [4.7-5.9]	26	7636	96.4 [95.6-97.1]	< 0.001	0.815	
Northern America	82.6 [77.8-86.9]	NA	NA	1	270	NA	1	NA	
South-East Asia	64.7 [57.3-71.7]	NA	NA	1	170	NA	1	NA	
Western Pacific	51.3 [32.1-70.3]	[0-100]	6.1 [4.6-8.1]	4	1304	97.3 [95.3-98.5]	< 0.001	0.705	
Sample type									< 0.001
Nasal secretions	50 [36.5-63.5]	[1.6-98.4]	4 [2.8-5.8]	4	902	93.9 [87.4-97]	< 0.001	0.116	
Nasopharyngeal secretions	61 [56.8-65.2]	[34-84.9]	5 [4.6-5.5]	40	14053	96 [95.2-96.6]	< 0.001	0.465	
Throat secretions	24.5 [20.4-28.9]	NA	NA	1	396	NA	1	NA	
RV									
Study period									0.391
Continuous study period	20.4 [16.9-24]	[6.3-39.6]	3.3 [2.8-3.8]	24	6199	90.8 [87.7-93.2]	< 0.001	0.314	
Interrupted time series study	18 [13.7-22.7]	[4.5-37.8]	4.2 [3.5-5.1]	11	5944	94.4 [91.8-96.2]	< 0.001	0.178	
WHO Region									< 0.001
America	17.8 [13.6-22.4]	[5.5-34.9]	3.2 [2.5-4.2]	9	4570	90.5 [84.2-94.3]	< 0.001	0.187	
Eastern Mediterranean	18.8 [8.3-32.3]	NA	4.9 [2.9-8.3]	2	1072	95.9 [88.4-98.6]	< 0.001	NA	


	Prevalence [95% CI]	95% Prediction interval	H [95% CI]	N Studies	N Cases	I2 [95% CI]	P-Value Heterogeneit y	P-Value Egger test	P-value subgroup difference
Europe	19.3 [15.9-23]	[5.1-39.5]	3.6 [3.1-4.1]	24	6557	92.2 [89.7-94.1]	< 0.001	0.905	
Western Pacific	33.5 [30.2-36.8]	NA	NA	1	768	NA	1	NA	
Sample type									0.243
Nasal secretions	12.7 [3.9-25.4]	[0-100]	4.7 [3.1-6.9]	3	808	95.4 [89.9-97.9]	< 0.001	0.762	
Nasopharyngeal secretions	20 [17.3-22.8]	[7.2-37]	3.6 [3.2-4]	33	12159	92.2 [90.1-93.9]	< 0.001	0.441	
HBoV									
Study period									0.09
Continuous study period	9.4 [6.4-12.9]	[0.1-29.1]	4.5 [4-5.2]	19	6897	95.2 [93.6-96.3]	< 0.001	0.497	
Interrupted time series study	5.1 [2.2-9.1]	[0-30.4]	2.4 [1.5-3.9]	4	985	82.9 [56.4-93.3]	0.001	0.386	
WHO Region									< 0.001
America	4.7 [0-15.2]	[0-100]	3.8 [2.4-5.9]	3	525	93.1 [83.1-97.2]	< 0.001	0.11	
Eastern Mediterranean	4 [2.9-5.3]	NA	1	2	1072	0	0.913	NA	
Europe	9 [5.4-13.5]	[0-33.4]	4.9 [4.3-5.7]	16	4947	95.9 [94.5-96.9]	< 0.001	0.884	
Western Pacific	11.6 [10.3-13]	[4.3-21.7]	1 [1-2.9]	3	2162	0 [0-88.3]	0.411	0.47	
Sample type									0.545
Nasal secretions	6.6 [2.7-12]	[0-97]	2.6 [1.5-4.5]	3	808	85.6 [57.9-95.1]	0.001	0.344	
Nasopharyngeal secretions	8.4 [5.4-12]	[0-29.4]	5 [4.4-5.7]	20	7502	96 [94.9-96.9]	< 0.001	0.784	
Throat secretions	9.8 [7.1-13]	NA	NA	1	396	NA	1	NA	
HAdV									
Study period									0.081
Continuous study period	6.6 [4.7-8.8]	[0.3-18.8]	3 [2.5-3.5]	22	5786	88.6 [84.1-91.8]	< 0.001	0.081	
Interrupted time series study	3.7 [1.6-6.5]	[0-20.2]	1.9 [1.1-3.2]	4	948	72 [20.7-90.1]	0.013	0.501	
WHO Region									< 0.001
America	1.5 [0.4-3.2]	[0-31]	1.2 [1-3.6]	3	525	24.9 [0-92.2]	0.264	0.454	

	Prevalence [95% CI]	95% Prediction interval	H [95% CI]	N Studies	N Cases	12 [95% CI]	P-Value Heterogeneit y	P-Value Egger test	P-value subgroup difference
Eastern Mediterranean	6.9 [4.6-9.6]	[0-51.6]	1.6 [1-3]	3	1240	61.8 [0-89.1]	0.073	0.177	
Europe	6.3 [4.5-8.4]	[0.7-16.4]	2.3 [1.9-2.9]	18	3931	81.8 [72.2-88]	< 0.001	0.543	
Northern America	5.9 [3.4-9.1]	NA	NA	1	270	NA	1	NA	
Western Pacific	18.1 [15.5-20.9]	NA	NA	1	768	NA	1	NA	
Sample type									0.532
Nasal secretions	7.3 [4.6-10.4]	NA	NA	1	316	NA	1	NA	
Nasopharyngeal secretions	6 [4.2-8.1]	[0.1-18.5]	3.1 [2.6-3.6]	25	6418	89.3 [85.5-92.1]	< 0.001	0.092	
HPIV									
Study period									0.005
Continuous study period	6.7 [4.6-9.1]	[0.1-20.5]	3.3 [2.8-3.9]	20	5687	91 [87.5-93.5]	< 0.001	0.943	
Interrupted time series study	2.8 [1.4-4.6]	[0-10.3]	2.2 [1.6-3.1]	8	2246	79.3 [59.6-89.4]	< 0.001	0.622	
WHO Region									< 0.001
America	6 [0.8-15]	[0-67.2]	4.4 [3.1-6.2]	4	980	94.8 [89.8-97.4]	< 0.001	0.166	
Eastern Mediterranean	11.6 [6.8-17.4]	[0-95.4]	2.7 [1.6-4.6]	3	1240	86.4 [60.6-95.3]	0.001	0.424	
Europe	3.9 [2.7-5.3]	[0.3-10.8]	2.1 [1.7-2.7]	19	4675	78.3 [66.7-85.9]	< 0.001	0.283	
Northern America	8.1 [5.2-11.7]	NA	NA	1	270	NA	1	NA	
Western Pacific	13.7 [11.3-16.2]	NA	NA	1	768	NA	1	NA	
Sample type									0.086
Nasal secretions	2.8 [0.8-5.9]	[0-76.1]	2.1 [1.2-3.8]	3	808	78.1 [29.5-93.2]	0.01	0.718	
Nasopharyngeal secretions	5.8 [4-7.9]	[0-19]	3.4 [2.9-3.9]	25	7125	91.4 [88.5-93.5]	< 0.001	0.969	
HMPV									
Study period									0.005
Continuous study period	6.3 [5.2-7.4]	[2.6-11.2]	1.7 [1.3-2.1]	24	7018	64.3 [44.8-76.9]	< 0.001	0.012	
Interrupted time series study	3.1 [1.5-5.1]	[0-11.8]	2.3 [1.6-3.3]	7	2066	81.4 [62.6-90.8]	< 0.001	0.735	

	Prevalence [95% CI]	95% Prediction interval	H [95% CI]	N Studies	N Cases	12 [95% CI]	P-Value Heterogeneit y	P-Value Egger test	P-value subgroup difference
WHO Region									0.443
America	5.4 [1.6-11.1]	[0-33.5]	3 [2.1-4.4]	5	1036	89 [77-94.7]	< 0.001	0.117	
Eastern Mediterranean	6.2 [4-8.9]	NA	NA	1	369	NA	1	NA	
Europe	5.7 [4.4-7.2]	[1.2-12.8]	2 [1.7-2.5]	21	5355	76.1 [63.6-84.3]	< 0.001	0.017	
Northern America	3.3 [1.5-5.9]	NA	NA	1	270	NA	1	NA	
South-East Asia	3.5 [1.2-6.9]	NA	NA	1	170	NA	1	NA	
Western Pacific	5.5 [4.5-6.7]	[0-20.3]	1.3 [1-2.3]	3	2708	38.6 [0-80.8]	0.196	0.692	
Sample type									0.198
Nasal secretions	3.7 [1.4-7]	[0-25.9]	2.8 [1.8-4.4]	4	1750	87.6 [70.5-94.8]	< 0.001	0.655	
Nasopharyngeal secretions	5.7 [4.6-6.8]	[1.6-11.8]	2 [1.7-2.4]	28	8158	74.7 [63.5-82.5]	< 0.001	0.017	
Influenza									
Study period									0.014
Continuous study period	4 [2.6-5.8]	[0-12.8]	2.5 [2-3.1]	16	4325	84.4 [76.1-89.9]	< 0.001	0.055	
Interrupted time series study	1.9 [1-3]	[0-5.9]	1.6 [1.1-2.4]	8	2246	62.8 [20-82.7]	0.009	0.313	
WHO Region									0.058
America	2.8 [0.5-6.4]	[0-28]	2.5 [1.6-4]	4	980	83.9 [59.4-93.6]	< 0.001	0.426	
Eastern Mediterranean	1.1 [0.2-2.5]	NA	NA	1	369	NA	1	NA	
Europe	3.5 [2.2-5]	[0-11.7]	2.4 [2-3]	18	4454	83.3 [74.8-88.9]	< 0.001	0.034	
Western Pacific	3.3 [2.1-4.6]	NA	NA	1	768	NA	1	NA	
Sample type									0.677
Nasal secretions	2.2 [0-9.2]	[0-100]	4.5 [3-6.7]	3	808	95 [88.8-97.8]	< 0.001	0.74	
Nasopharyngeal secretions	3.2 [2.3-4.4]	[0.2-9.1]	2.1 [1.7-2.6]	21	5763	77.3 [65.7-85]	< 0.001	0.006	
HCoV									
Study period									0.589
Continuous study period	3.1 [2-4.4]	[0-9.8]	2.3 [1.9-2.8]	20	5365	80.9 [71.3-87.2]	< 0.001	0.789	

	Prevalence [95% CI]	95% Prediction interval	H [95% CI]	N Studies	N Cases	12 [95% CI]	P-Value Heterogeneit y	P-Value Egger test	P-value subgroup difference
Interrupted time series study	2.5 [0.8-5.1]	[0-14.6]	3 [2.2-4]	7	2066	88.7 [79.2-93.9]	< 0.001	0.717	
WHO Region									< 0.001
America	1.5 [0.8-2.4]	[0.2-3.7]	1 [1-2]	4	980	0 [0-75.5]	0.598	0.625	
Eastern Mediterranean	4.2 [1.4-8.4]	NA	2.7 [1.4-5.4]	2	1072	86.5 [46.7-96.6]	0.006	NA	
Europe	2.6 [1.5-4.1]	[0-10.4]	2.4 [2-3]	18	4223	83 [74.3-88.8]	< 0.001	0.639	
Northern America	10.7 [7.3-14.7]	NA	NA	1	270	NA	1	NA	
Western Pacific	4.4 [2.4-7]	NA	1.3 NA	2	886	37.7 NA	0.205	NA	
Sample type									0.071
Nasal secretions	1.1 [0-3.3]	[0-70]	2.1 [1.2-3.8]	3	808	77.7 [27.9-93.1]	0.011	0.79	
Nasopharyngeal secretions	3.2 [2.2-4.4]	[0-10.3]	2.4 [2-2.9]	24	6623	82.8 [75.5-88]	< 0.001	0.969	
EV									
Study period									0.466
Continuous study period	2.6 [1-4.7]	[0-13.3]	3.1 [2.4-3.9]	11	3254	89.4 [83-93.4]	< 0.001	0.716	
Interrupted time series study	3.6 [2.1-5.5]	[0-12.1]	1.3 [1-2.3]	4	948	44.1 [0-81.3]	0.147	0.304	
WHO Region									< 0.001
America	20.8 [12.4-30.6]	NA	NA	1	77	NA	1	NA	
Eastern Mediterranean	1.6 [0.5-3.2]	NA	NA	1	369	NA	1	NA	
Europe	2 [1.2-2.9]	[0.2-5.2]	1.5 [1.1-2.1]	12	2988	55.3 [14.5-76.6]	0.01	0.632	
Western Pacific	7.8 [6-9.8]	NA	NA	1	768	NA	1	NA	
Sample type									NA
Nasopharyngeal secretions	2.9 [1.6-4.5]	[0-11.4]	2.7 [2.2-3.3]	15	4202	86.1 [78.6-90.9]	< 0.001	0.886	

CI: confidence interval; RV: Rhinovirus; HCoV: Human Coronavirus; HPIV: Human Parainfluenzavirus; HMPV: Human Metapneumovirus; HRSV: Human Respiratory Syncytial Virus; HAdV: Human Adenovirus; HBoV: Human Bocavirus; EV: Enterovirus; NA: not applicable.



Azkur, 2014

Bekhof, 2019

Brand, 2012

Calvo, 2010

Janahi, 2017

Nascimento, 2010

Salvador García, 2012

Random effect meta-analysis

Overall random effect meta-analysis

Heterogeneity: $I^2 = 86.1\%$ [78.6%; 90.9%], $\tau^2 = 0.0057$, p < 0.0001

Residual heterogeneity: $I^2 = 92.7\%$ [92.0%; 93.3%], p = 0

Jartti, 2014

Ricart, 2013

Ricart, 2013

Richard, 2008

Su-Jin, 2018

Uyar, 2014

1

5

10

5

6

12

16

9

9

7

3

60

1

218 +

368 +

369 +

408 +

418 +

235 +

62 +

 \Diamond

20

40

60

4202 ♦

77

484

180

768

79803

142

1.82

2.29

7.04

1.36

1.63

2.94

20.78

2.15

1.86

3.89

1.28

7.81

1.61

2.86

13.26

80

0.4%

0.4%

0.4%

0.4%

0.4%

0.4%

0.4%

0.4%

0.4%

0.4%

0.4%

0.4%

0.4%

5.8%

[0.75; 5.27]

[3.43; 12.57]

[0.44; 3.14]

[0.60: 3.51]

[1.53; 5.08]

[12.37; 31.54]

[0.99; 4.05]

[0.85; 3.50]

[1.58; 7.85]


[0.26: 3.69]

[6.01; 9.94]

[0.04; 8.66]

[1.55; 4.52]

[10.98; 15.71] 100.0%



Random effect meta-analysis

Overall random effect meta-analysis

Residual heterogeneity: $I^2 = 82.4\%$ [78.6%; 85.5%], p < 0.0001

Heterogeneity: not applicable

314 ~

5

10 15 20 25

30

27430


0.32


2.00


[0.00; 1.36]

[1.40; 2.69] 100.0%

1.0%







S6 Fig. Funnel plot for publication for HAdV in people with bronchiolitis

